

Daichi Fujimoto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7475456/daichi-fujimoto-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

946
citations

15
h-index

30
g-index

44
ext. papers

1,228
ext. citations

3.6
avg, IF

3.82
L-index

#	Paper	IF	Citations
39	A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100265	1.4	1
38	Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100317	1.4	
37	Histologic transformation of epidermal growth factor receptor-mutated lung cancer.. <i>European Journal of Cancer</i> , 2022 , 166, 41-50	7.5	1
36	Alternating therapy with osimertinib and afatinib for treatment-naïve patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).. <i>Lung Cancer</i> , 2022 , 168, 38-45	5.9	0
35	Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. <i>European Journal of Cancer</i> , 2021 , 145, 183-193	7.5	4
34	Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature. <i>Respirology Case Reports</i> , 2021 , 9, e00741	0.9	2
33	Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. <i>BMC Cancer</i> , 2021 , 21, 346	4.8	5
32	Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. <i>European Journal of Cancer</i> , 2021 , 150, 63-72	7.5	5
31	Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. <i>Investigational New Drugs</i> , 2021 , 39, 853-859	4.3	0
30	A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).	4.9	3
29	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. <i>BMC Cancer</i> , 2020 , 20, 103	4.8	8
28	Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2020 , 21, e315-e328	4.9	22
27	Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. <i>Lung Cancer</i> , 2020 , 140, 8-18	5.9	37
26	Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). <i>ESMO Open</i> , 2020 , 5,	6	3
25	"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020 , 33, 4-17	9.8	73
24	Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. <i>Investigational New Drugs</i> , 2020 , 38, 1192-1195	4.3	1
23	Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. <i>Lung Cancer</i> , 2019 , 134, 274-278	5.9	38

22	Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 275-280	3.5	13
21	Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer. <i>Anticancer Research</i> , 2019 , 39, 2561-2567	2.3	2
20	A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). <i>Lung Cancer</i> , 2019 , 135, 175-180	5.9	13
19	Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab. <i>Investigational New Drugs</i> , 2019 , 37, 1257-1265	4.3	5
18	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). <i>Lung Cancer</i> , 2019 , 131, 128-133	5.9	15
17	Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). <i>Investigational New Drugs</i> , 2019 , 37, 1266-1273	4.3	21
16	Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 468-474	8.9	55
15	Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. <i>Lung Cancer</i> , 2018 , 119, 14-20	5.9	85
14	Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 377-386	8.9	39
13	Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. <i>Investigational New Drugs</i> , 2018 , 36, 952-954	4.3	9
12	Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 333-337	3.5	5
11	Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263. <i>Anticancer Research</i> , 2018 , 38, 6891-6895	2.3	14
10	Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials. <i>Clinical Lung Cancer</i> , 2018 , 19, e721-e734	4.9	21
9	Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study. <i>Clinical Lung Cancer</i> , 2018 , 19, e667-e673	4.9	9
8	Natural history and clinical characteristics of multiple pulmonary nodules with ground glass opacity. <i>Respirology</i> , 2017 , 22, 1615-1621	3.6	14
7	Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1798-1805	8.9	241
6	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2017 , 7, 11373	4.9	42
5	A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. <i>Lung Cancer</i> , 2017 , 111, 1-5	5.9	43

4	Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>PLoS ONE</i> , 2016 , 11, e0168465	3.7	34
3	Comparison of two transport systems available in Japan (TERUMO kenkiporter II and BBL Port-A-Cul) for maintenance of aerobic and anaerobic bacteria. <i>Journal of Infection and Chemotherapy</i> , 2014 , 20, 26-9	2.2	1
2	The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 1159-66	3.5	37
1	Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. <i>Lung Cancer</i> , 2013 , 80, 159-64	5.9	25